Candriam Luxembourg S.C.A. trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 57.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,010 shares of the company’s stock after selling 2,680 shares during the period. Candriam Luxembourg S.C.A.’s holdings in IDEXX Laboratories were worth $314,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Zions Bancorporation acquired a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $162,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after purchasing an additional 1,000 shares in the last quarter. SignalPoint Asset Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $200,000. Ledyard National Bank grew its holdings in shares of IDEXX Laboratories by 58.9% in the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock valued at $203,000 after purchasing an additional 480 shares in the last quarter. Finally, IBM Retirement Fund acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $213,000. 86.02% of the stock is currently owned by institutional investors and hedge funds.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $187.61 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. IDEXX Laboratories, Inc. has a twelve month low of $141.02 and a twelve month high of $198.73. The company has a market cap of $16,018.40, a P/E ratio of 63.81, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The company had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. During the same quarter in the previous year, the business posted $0.58 EPS. The firm’s revenue was up 14.2% on a year-over-year basis. equities analysts forecast that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
In other IDEXX Laboratories news, Director William T. End sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $184.48, for a total transaction of $737,920.00. Following the completion of the transaction, the director now owns 41,256 shares in the company, valued at approximately $7,610,906.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. Insiders have sold a total of 90,762 shares of company stock valued at $15,940,404 in the last quarter. 2.77% of the stock is currently owned by company insiders.
A number of research analysts recently weighed in on IDXX shares. Bank of America lifted their price objective on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a report on Monday, January 29th. BidaskClub upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Piper Jaffray Companies started coverage on shares of IDEXX Laboratories in a report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price objective for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $194.00.
TRADEMARK VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Shares Sold by Candriam Luxembourg S.C.A.” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://transcriptdaily.com/2018/02/25/idexx-laboratories-inc-idxx-shares-sold-by-candriam-luxembourg-s-c-a.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.